Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 187-197

  Boulenc, Xavier ^a   Djebli, Nassim ^a   Shi, Juan ^b   Perrin, Laurent ^a   Brian, William ^b   Van Horn, Robert ^b   Hurbin, Fabrice ^a  

^a SANOFI   (France)

^b Drug Disposition Disposition Safety and Animal Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG METABOLITE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTEIN INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; META ANALYSIS (TOPIC); MOLECULAR DYNAMICS; MOLECULAR MODEL; MONOTHERAPY; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; OMEPRAZOLE; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84455194048     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040394     Document Type: Article

References (39)

1. Andersson T, Andrén K, Cederberg C, Lagerström PO, Lundborg P, and Skånberg I (1990) Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 29:557-563. (Pubitemid 20161305)
2. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, and Dubar M (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89:65-74.
3. Boulenc X, Schmider W, and Barberan O (2011) In vitro/in vivo correlation for drug-drug interactions, in Drug Discovery and Evaluation: Methods in Clinical Pharmacology (Vogel HG, Maas J, and Gebauer A eds) 2nd ed. Springer, Berlin.
4. Chen BL, Chen Y, Tu JH, Li YL, Zhang W, Li Q, Fan L, Tan ZR, Hu DL, Wang D, et al. (2009) Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol 49:574-581.
5. Close SL (2011) Clopidogrel pharmacogenetics: metabolism and drug interactions. Drug Metabol Drug Interact 26:45-51.
6. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, and Bonnet JL (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 54:1149-1153.
7. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
8. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, and Salazar DE (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735-741. (Pubitemid 46625113)
9. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, and Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260.
10. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
11. Gurbel PA, Antonino MJ, and Tantry US (2009) Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 5:989-1004.
12. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, and Ikeda T (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 37:2145-2152.
13. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-727.
14. Houston JB (1986) Drug metabolite kinetics, in Pharmacokinetics: Theory and Methodology (Rowland M and Tucker G eds) pp 131-162, Pergamon Press, New York.
15. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247. (Pubitemid 44497506)
16. Imai T and Ohura K (2010) The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 11:793-805.
17. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, and Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
18. Kim KA, Park PW, Hong SJ, and Park JY (2008) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236-242.
19. Li XQ, Andersson TB, Ahlström M, and Weidolf L (2004) Comparison of inhibitory effects on the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827. (Pubitemid 38955611)
20. Lins R, Broekhuysen J, Necciari J, and Deroubaix X (1999) Pharmacokinetic profile of 14Clabeled clopidogrel. Semin Thromb Hemost 25 (Suppl 2):29-33.
21. Liu KH, Kim MJ, Shon JH, Moon YS, Seol SY, Kang W, Cha IJ, and Shin JG (2005) Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 35:27-38. (Pubitemid 40459215)
22. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037. (Pubitemid 30660356)
23. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362.
24. Pang KS (1995) Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite. Drug Metab Dispos 23:166-177.
25. Paris B, Yerino P, Buckley D, Ogilvie BW, and Parkinson A (2008) The proton pump inhibitors omeprazole and rabeprazole but not lansoprazole and pantoprazole are in vitro time-dependent inhibitors of CYP2C19 (Abstract). Drug Metab Rev 40 (Suppl 1):89.
26. Rowland M and Martin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinetic Biopharm 1:553-567.
27. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
28. Sangkuhl K, Klein TE, and Altman RB (2010) Clopidogrel pathway. Pharmacogenet Genomics 20:463-465.
29. Shi S and Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951.
30. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, et al. (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937. (Pubitemid 34014349)
31. Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, and Dubar M (2011) Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 90:287-295.
32. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467-1476.
33. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, Hurbin F, et al. (2011) An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696-705.
34. Umemura K, Furuta T, and Kondo K (2008) The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6:1439-1441. (Pubitemid 352016331)
35. Venkatakrishnan K and Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845-852. (Pubitemid 40686639)
36. Votano JR, Parham M, Hall LM, Hall LH, Kier LB, Oloff S, and Tropsha A (2006) QSAR modeling of human serum protein binding with several modeling techniques utilizing structure- information representation. J Med Chem 49:7169-7181. (Pubitemid 44886002)
37. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
38. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, and Shin SG (2001) Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69:266-273. (Pubitemid 32382510)
39. Zhang H, Ragueneau-Majlessi I, and Levy RH (2009) Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metab Lett 3:287-289.